Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Commercialization symbols : Pfe save search
Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States
Published: 2022-01-05 (Crawled : 17:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.73%
H: 0.0%
C: 0.0%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 1.38%
H: 0.0%
C: 0.0%
BHVN | News 0 d | $42.16 -4.25% 0.85% 3.7M
|
Health Technology
|
| O: 0.43%
H: 0.9%
C: -4.35%
commercialization collaboration
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States
Published: 2021-11-09 (Crawled : 13:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.64%
H: 0.0%
C: 0.0%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
BHVN | News 0 d | $42.16 -4.25% 0.85% 3.7M
|
Health Technology
|
| O: -20.3%
H: 0.0%
C: 0.0%
commercialization collaboration
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471
Published: 2021-07-22 (Crawled : 12:15) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.24%
H: 1.05%
C: 0.85%
ARVN | $34.3 2.54% 2.48% 800K
|
Health Technology
|
| O: 7.99%
H: 7.73%
C: 0.91%
collaboration commercialization
Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer
Published: 2021-04-08 (Crawled : 21:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.14%
H: 0.53%
C: 0.0%
CELC | $16.4 -3.59% -3.72% 200K
|
Commercial Services
|
| O: -1.04%
H: 0.42%
C: 0.42%
cancer breast cancer commercialization license
Pyxis Oncology Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Multiple Antibody-Drug Conjugates
Published: 2021-03-18 (Crawled : 17:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.73%
H: 1.24%
C: 0.68%
antibody drug commercialization license
Industry Players in Heparin Market Working Concertedly to Commercialize Affordable and Effacious Products, Market to Garner CAGR of 6.8% during 2019 - 2027
Published: 2021-03-10 (Crawled : 17:05) - prnewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.55%
H: 1.44%
C: 0.84%
BAX | News | $39.65 0.33% 0.0% 2.3M
|
Health Technology
|
| O: 0.1%
H: 0.67%
C: 0.48%
ford commercialization
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
Published: 2020-12-28 (Crawled : 12:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.24%
H: 0.59%
C: -1.45%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 32.66%
H: 2.39%
C: -9.18%
collaboration commercialization announces collaboration health
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.